TABLE 7.
Serum IgG CT antibody titers of vaccinees
| Vaccine | n | GM ELISA titera (25th–75th centiles) at indicated day postinjection
|
|||
|---|---|---|---|---|---|
| 0 (preinjection) | 28 | 70 | 230 | ||
| DeALPS-CT-1 | 19 | 0.48 (0.38–0.70) | 6.31 (4.92–19) | 7.68 (5.34–19) | 2.68 (1.48–6.54) |
| DeALPS-CT-2 | 19 | 0.72 (0.48–0.94) | 11.5 (2.28–53) | 13.2 (3.06–53) | 5.08 (1.83–9.16) |
| DeALPS | 19 | 0.73 (0.45–1.07) | 1.26 (0.75–1.66) | 1.09 (0.52–1.66) | 1.00 (0.48–1.73) |
| Cellularb | 18 | 0.67 (0.49–0.91) | 1.19 (0.68–2.44) | 1.36 (0.78–2.44) | 0.95 (0.46–1.85) |
a
Expressed as in Table 3. Plates were coated with CT-1 (0.5 μg/well). Comparisons: 6.31, 11.5 versus 1.26, 1.19, P < 0.001; 5.08 versus 1.00, 0.95, P < 0.002; 2.68 versus 1.00, 0.95, P = 0.03; 5.08 versus 2.68, 11.5 versus 6.31, and 13.2 versus 7.68, not significant.
b
Wyeth-Ayerst Laboratories, containing 4 × 109 organisms each of V. cholerae O1 serotypes Inaba and Ogawa.